Kornimate/medical-research-clean huggingface dataset:
cardiovascular, pulmonary, and integrative functional phenotypes in covid-19 survivors - effect of fenofibrate

Conditions: Covid19

Summary: the international multicenter fenofibrate as a metabolic intervention for covid-19 (fermin) trial is being executed. the trial is testing a short intervention (10 days of fenofibrate therapy) on 30-day outcomes in covid-19. the overarching goal of this sub-study is to explore the impact of fenofibrate on key longer term phenotypes of vascular, cardiac and pulmonary health, integrated cardiopulmonary function, persistent/chronic symptoms and quality of life.

the international multicenter fenofibrate as a metabolic intervention for covid-19 (fermin) trial is being executed. the aim of this trial is to assess the impact of fenofibrate (administered for 10 days) to improve clinical outcomes in patients with covid-19, assessed at 30 days. however, given the accumulating evidence of chronic / long term sequelae of covid-19, it is important to assess the long-term impact of this intervention in this patient population. the overarching goal of this substudy is to assess the impact of fenofibrate on key intermediate phenotypes of vascular, cardiac and pulmonary health. we also aim to address the impact of fenofibrate therapy (administered during the acute covid-19 episode as part of the parent fermin trial) on long-term integrated cardiopulmonary function, persistent/chronic symptoms and quality of life. we will accomplish this via enrollment of previous fermin participants from the university of pennsylvania, in an phenotyping study designed to assess vascular, cardiac and pulmonary status several months after the index episode of covid-19. we will perform these assessments \~6 months after initial randomization, among 40 fermin trial participants enrolled at the university of pennsylvania.

Eligibility criteria:
inclusion criteria: • having been eligible, enrolled and randomized in the parent fermin trial, completing all study procedures up to the 30-day time point (as specified in the parent protocol). exclusion criteria * prisoners/incarcerated individuals; * pregnancy (potentially eligible patients of reproductive age will undergo a pregnancy test). this exclusion is due to the fact that pregnancy may confound the various cardiopulmonary phenotypes assessed in this study * inability to provide informed consent. * history of cardiovascular disease (defined as heart failure, myocardial infarction, coronary revascularization, serious arrhythmia, stroke, or peripheral artery disease), glomerular disease or polycystic kidney disease prior to the index covid-19 episode. * estimated glomerular filtration rate \<30 ml/min/1.73m2 prior to the index covid-19 episode.
platelet rich fibrin+1.2% atorvastatin in treatment of mandibular degree ii furcation defects

Conditions: Furcation Defects

Summary: the present study was designed to explore the effectiveness of prf combined with 1.2% atv gel in treatment of mandibular degree ii furcation defects in comparison to prf and open flap debridement (ofd) alone.

background: a variety of regenerative materials have been tried since many years for the treatment of furcation defects. platelet-rich fibrin (prf), a pool reservoir of platelet concentrate with growth factors and atorvastatin (atv), a potent member of statin group are known to promote periodontal tissue regeneration. the aim of the present study is to explore the effectiveness of prf combined with 1.2% atv gel in treatment of mandibular degree ii furcation defects in comparison to prf and open flap debridement (ofd) alone. methods: eighty two mandibular furcation defects were treated with either ofd alone (group 1), ofd with prf (group 2), and ofd with prf+1.2% atv gel (group 3).clinical parameters like probing depth (pd), relative vertical clinical attachment level (rvcal), relative horizontal clinical attachment level (rhcal), modified sulcus bleeding index (msbi) and site specific plaque index (pi) were recorded at baseline and 9 months post-operatively. the radiological assessment of bone defect fill was done at baseline and 9 months, using computer-aided software.

Eligibility criteria:
inclusion criteria: * buccal degree ii furcation defects in endodontically vital, asymptomatic mandibular first and second molars with a radiolucency in the furcation area on an intraoral periapical radiograph with probing depth (pd) ≥ 5mm and horizontal ≥ pd 3mm after phase i therapy i.e, scaling and root planing (srp); * no history of antibiotic or periodontal therapy in the preceding 6 months. exclusion criteria: * aggressive periodontitis patients * systemic conditions known to affect the periodontal status; * medications known to affect the outcomes of periodontal therapy; * hematological disorders and insufficient platelet count (\<100,000/mm3); * pregnancy/lactation; * smoking and tobacco use in any form * immunocompromised individuals; * those having unacceptable oral hygiene (plaque index \[pi\] \>1.5). * teeth with furcation involvement, non-vital teeth, and carious teeth indicated for restorations and mobility of at least grade ii were also excluded.
different intravitreal injection techniques and pain level

Conditions: Injection Site Discomfort

Summary: the purpose of this study is to determine whether certain intravitreal injection techniques cause less pain than others and would therefore be beneficial for the patient's well being.


Eligibility criteria:
inclusion criteria: * patients receiving intravitreal anti vascular endothelial growth factor (vegf) injections * informed consent exclusion criteria: * dementia or any other reason for cognitive deterioration * technical limitations not allowing injecting by the protocol
saem: a serious game for emotional regulation problems in adolescents

Conditions: Adolescents

Summary: this study aims to assess the effects of an intervention to improve emotional regulation skills in adolescents with affective (anxiety and/or depression) and behavioral problems.

emotional regulation skills and strategies are a protective factor against various problems and psychopathologies. the development and maintenance of affective symptoms are usually very harmful to the adolescent and for his/her family and social environment and can lead to other more serious psychological problems (depression, anxiety, adaptive disorders, etc.) or problems of socio-educational maladjustment. this study aims to improve the emotional regulation of adolescents who present affective symptoms related to anxiety, depression, or behavioral problems, such as difficulties in their interpersonal relationships, impulsivity, anxiety, anger attacks, low tolerance to frustration, apathy, or sadness. the intervention program, applied through a video game, is an intervention protocol for emotional well-being that has been tested and validated in an adolescent population with emotional and behavioral problems.

Eligibility criteria:
inclusion criteria: * between 12 and 16 years old * show affective symptoms associated with depression and anxiety or behavior problems * show willingness to participate in the research study * understand written and spoken spanish * show stability in treatment dosage, if taking medication. exclusion criteria: * exhibit incapacitating neurological and/or intellectual impairment * have a diagnosis of severe mental disorder * substance abuse addiction or dependence

Keywords: emotion regulation adolescents serious game anxiety behavior problems
multiple ascending dose study of bms-582949 in patients with stable rheumatoid arthritis on the methotrexate background

Conditions: Rheumatoid Arthritis

Summary: the purpose of this clinical research study is to learn if it is safe for rheumatoid arthritis patients to take bms-582949 along with methotrexate.


Eligibility criteria:
inclusion criteria: * age 18-70 years * diagnosis of ra for ≥6 months * swollen or tender joint or esr \>uln. subject must be on stable doses of mtx * women of childbearing potential exclusion criteria: * serum transaminase levels \>uln * ck\>uln * cannot have taken orencia or remicade within 8 weeks of baseline, humira or enbrel within 4 weeks of baseline * use of h2 blockers or proton pump inhibitors while on study
body composition, glucose metabolism, insulin resistance and gene expression in muscle cells in healthy overweight women

Conditions: Obesity; Type 2 Diabetes; Polycystic Ovary Syndrome

Summary: in this study, we will clarify the degree of insulin resistance and characterise muscle glucose metabolism and gene expression in a group of overweight healthy women. the study will clarify how overweight influences body glucose metabolism and thereby in the long-run increases the risk for developing type 2 diabetes. moreover, the study may clarify why some overweight women develop hormone disorders and diabetes while others remain healthy. the study is essential as many patients suffer from diseases aggravated by overweight. in addition, a genetic disposition for diabetes or polycystic ovary syndrome may give rise to the disease if the patient gains weight. it is therefore important that weight-matched control subjects are included in projects with overweight patients. this clinical trial includes 10 overweight women with regular hormones and normal level of male sex hormone. the patients included must be healthy, take no medications influencing the study results. the subjects must take no contraceptive pills or receive any other hormone treatment. in connection with the investigation, the following will be carried out on all patients: clinical examination, blood tests, hyperinsulinaemic euglycaemic clamp, muscle biopsies, bone scan. the purpose of the study is to gain more knowledge of how overweight influences women's risk of developing hormone diseases and diabetes.


Eligibility criteria:
inclusion criteria: * regular menses, i.e. cyclus length 25-34 days * premenopausal * ferrimann-gallway score \< 2 * bmi \> 27 kg/m2 * normal total testosterone value \< 3.5 nmol/l exclusion criteria: * age \<18 years * contraceptive pills within the past 3 months * postmenopausal (increased fsh) * diabetes mellitus * endocrine or other disease requiring treatment * eating disorder or other psychiatric history * drug use known to influence parameters investigated in this trial * pregnancy

Keywords: polycystic ovary syndrome growth hormone insulin resistance overweight glucose metabolism
low-level laser therapy in chronic autoimmune thyroiditis

Conditions: Autoimmune Thyroiditis

Summary: the purpose of this study is to evaluate whether low-level laser therapy is effective in ameliorating the thyroid function of patients with hypothyroidism caused by chronic autoimmune thyroiditis.

chronic autoimmune thyroiditis (cat) is the most common cause of hypothyroidism in iodine-replete areas. an autoimmune dysfunction causes humoral and cellular responses that lead progressively to thyroiditis. there is no effective therapy available that can change the natural history of cat, which presents a high incidence of hypothyroidism and requires continuous treatment with levothyroxine (lt4). laser light can be valuable since the local and systemic actions of low-level laser therapy (lllt) have been shown to be effective in treating autoimmune diseases, such as rheumatoid arthritis and sjogren's syndrome. there is also evidence suggesting that lllt can facilitate regeneration of various tissues and, in animal thyroids, can lead to improvement in microcirculation and increases in serum triiodothyronine (t3) and thyroxine (t4) levels. since the lllt is a non-invasive, cost-effective and painless procedure, the objective of this randomized clinical trial was to evaluate the effectiveness of lllt in patients with hypothyroidism caused by chronic autoimmune thyroiditis, based on patients' thyroid function, their concentration of thyroid autoantibodies, and the parameters of their ultrasonography study.

Eligibility criteria:
inclusion criteria: * patients previously diagnosed with hypothyroidism induced by chronic autoimmune thyroiditis (cat). the presence of hypothyroidism, laboratory measurements and ultrasonography criteria were applied to diagnose cat. * significantly elevated concentrations of thyroid peroxidase (tpoab) and/or thyroglobulin (tgab) autoantibodies * ultrasonography results consistent with cat * patients undergoing lt4 treatment * normal (or almost normal) levels of triiodothyronine (t3), thyroxine (t4), free t4 and thyrotropin (tsh) exclusion criteria: * use of immunosuppressants, immunostimulants, or other drugs that could interfere with the production, metabolism and transport of thyroid hormones * cat with normal thyroid function * cat with subclinical hypothyroidism * thyroid nodules * hypothyroidism stemming from post-partum thyroiditis (up to 18 months after gestation) * history of graves' disease * thyrotropin receptor antibody (trab) detectable * prior treatment with radioiodine * tracheal stenosis * pregnancy * history of ionizing irradiation and/or neoplasia in the cervical area * previous surgical intervention in the thyroid * thyroid hypoplasia * ectopic thyroid * serious illness (cancer, ischemic coronary artery disease, stroke, kidney or liver failure, etc.)

Keywords: autoimmune thyroiditis, laser, therapy, thyroid, ultrasound
a randomised controlled trial of iodide supplementation in preterm infants follow-up at 2 years

Conditions: Transient Hypothyroxinemia

Summary: the purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.

iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. the recommended iodine intake in parenteral nutrition regimens is 1 μg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. in the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. as many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the i2s2 trial was designed as a uk multicentre randomised controlled trial to establish whether iodine supplementation of preterm infants benefits neurodevelopment.

Eligibility criteria:
inclusion criteria: * all infants born under 31 weeks gestation exclusion criteria: * mother exposed to excess iodine during pregnancy or delivery

Keywords: hypothyroxinemia preterm infants iodine neurodevelopmental outcome iodine supplementation randomised controlled trial
safety and immunogenicity of pentavalent meningococcal conjugate vaccine (eunmcv-5) in healthy adults aged 19 to 55 years old

Conditions: Infection, Meningococcal

Summary: phase i study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of meningococcal (group a, c, w-135, x, and y)-crm197 conjugate vaccine


Eligibility criteria:
inclusion criteria: * subjects 19 to 55 years of age * written informed consent * available for all visits and telephone calls scheduled for the study exclusion criteria: * previous or suspected disease caused by n. meningitides * household and/or intimate exposure to an individual with culture-proven n. meningitides infection within 60 days prior to screening * serious acute, chronic or progressive disease as determined by investigator * history of alcohol or substance abuse
reliability and validity of the turkish version of the multiple sclerosis knowledge questionnaire

Conditions: Multiple Sclerosis

Summary: multiple sclerosis knowledge questionnaire (mskq) is a 25-item self administered questionnaire assessing a patient's level of knowledge regarding multiple sclerosis (ms). turkish translation of the questionnaire was prepared and participants in the annual patient education seminar in the investigators' university hospital were asked to answer these questions before and after the seminar.their results were analysed to assess their level of knowledge about their disease.

multiple sclerosis knowledge questionnaire was developed in italy (1) and was reported to be useful in measuring patients' level of knowledge about their disease. the english version of the questionnaire was translated into turkish by three physicians than back translated into english by two separate linguists. initially 5 ms patients were asked to answer this first version of the questionnaire and report any difficulties in understanding the items. their feedback was used to give the questionnaire its final shape. for the validation stage, patients that were diagnosed as having ms and who attended the annual ms patient education seminar were enrolled into the study. they answered the questions twice, before and after the seminar. their answers were analysed to measure their level of knowledge about their disease.

Eligibility criteria:
inclusion criteria: * diagnosed as having multiple sclerosis * attends the annual patient education seminar at the investigators' university hospital * older than 18 years of age * can read and write exclusion criteria: * does not accept to answer the questionnaire * unable to answer the questions due to a cognitive impairment

Keywords: multiple sclerosis surveys and questionnaires diagnostic self evaluation
natural history of urticaria pigmentosa in children

Conditions: Urticaria Pigmentosa

Summary: the purpose of this study is to determine how long the skin lesions usually last and what kind of symptoms and signs children with urticaria pigmentosa may develop over the years. this information will allow physicians to better care for patients who have been diagnosed with this disease and to provide their parents with more complete information regarding what to expect for the future of their child. this research is being done because many unanswered questions remain regarding children with urticaria pigmentosa and its course.

this study involves children, of age 0-18 years old who are diagnosed with urticaria pigmentosa during their visit at the pediatric dermatology clinic. parents and child will be interviewed to gain medical and family history, in addition, the doctor will perform a physical exam and take a photograph. children older than 4 years of age will complete the "children dermatology life quality index." children less than 4 years of age with an active disease will have laboratory tests requiring a sample of blood (1 teaspoon). patients will receive $50 for their first office visit as financial reimbursement for participating in the study.

Eligibility criteria:
inclusion criteria: * age 0-18 years old at diagnosis of up * 3 or more mastocytomas (diagnosis can be based on clinical exam; biopsy only necessary if diagnosis is in question) * patients recruited from children's hospital of wisconsin dermatology clinic exclusion criteria: * less than 3 mastocytomas * diffuse mastocytosis * tmep * residence is out of wisconsin/illinois area or the united states

Keywords: urticaria pigmentosa mastocytosis mastocytomas
18f-fdgal pet/ct and pet/mri in patients with hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is the most common primary liver tumor and the fourth leading cause of cancer-related death worldwide. in denmark, the incidence of hcc is 5.2 per 100.000 population per year with a dismal prognosis as the median survival time is just 7.7 months. extrahepatic spread of hcc is common at advanced stages with haematogenous spread to lungs, bones and adrenal glands or lymphatic spread to regional lymph nodes. the majority of patients who develop hcc have cirrhosis of the liver and in these patients, diagnosis can be made non-invasively with characteristic contrast-enhancement pattern on computed tomography (ct) and/or magnetic resonance imaging (mri). although contrast-enhanced ct and mri are considered equal in current guidelines, mri may have a better sensitivity especially for small lesions. positron emission tomography (pet) is a molecular imaging technique based on the injection of a very small dose of a tracer substance labelled with a positron emitting radioisotope. pet with the glucose tracer 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose (18f-fdg) is an important tool in the staging of many cancer forms, but it is not included in the international guidelines for management of hcc because of suboptimal sensitivity of only up to 50-60 % for hcc situated in the liver. in aarhus, the liver specific tracer 18f-fdgal has been developed. it is a fluorine-18 labelled galactose analogue which in the human body is trapped in hepatocytes by phosphorylation by galactokinase. the first study of the diagnostic use of 18f-fdgal pet/ct in patients suspected of having hcc was published in 2011. the study showed good clinical potential for 18f-fdgal as a tracer for detection of intra- as well as extrahepatic hcc. the aim of the present project is to establish the clinical impact and utilization of 18f-fdgal pet/ct and pet/mri in patients suspected of having hcc or diagnosed with hcc, for staging and evaluation of treatment response including effect of treatment on liver function. hypotheses: i. adding 18f-fdgal pet/ct or pet/mri to diagnostic work-up of patients suspected of or diagnosed with hcc will add to the establishment of a definitive diagnosis and improve staging and thus choice of treatment. ii. the uptake pattern of 18f-fdgal in hcc provides prognostic information and can be used to evaluate regional metabolic liver function before and after loco-regional treatment.


Eligibility criteria:
inclusion criteria: * newly-referred patients suspected of or diagnosed with hcc * age above 18 years exclusion criteria: * the patient does not want to take part in the study * the responsible investigator determines that the patient is not qualified for a pet scan. * patients who are offered systemic chemotherapy or best supportive care will be excluded. * renal insufficiency (estimated glomerular filtration rate \[egfr\] \<30 ml/min/1.73 m2 body surface area). * pregnant or nursing patients.
a prospective clinical cohort study on stratified treatment of rhabdomyosarcoma based on risk factors.

Conditions: Rhabdomyosarcoma; Pediatric Cancer

Summary: the purpose is to explore the efficacy and safety of the sysucc-rms regimen for pediatric rms patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.


Eligibility criteria:
inclusion criteria: 1. 0 years \< age \< 18 years old, regardless of gender; 2. tumor patients diagnosed by histopathology or bone marrow cytology; 3. patients are treated for the first time; 4. ecog score ≤ 2; 5. the expected survival time is more than 8 months; 6. patient's parent or guardian signs informed consent. exclusion criteria: 1. combined with immunodeficiency disease 2. second tumor